Clinical trials: Hand-foot Syndrome
Grade 2 Hand-foot Syndrom
Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
- Trial name
- OCRP (NCT03612011)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Quanta Medical
Palmar-plantar Erythrodysesthesia (PPE)
Testing the Effectiveness of Henna on Managing PPE
The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most…
- Trial name
- NCT01751893
- Testing
- Henna
- Where
- Cyprus
- Volunteers
- 56 people
- Sponsor
- Cyprus University of Technology
Hand-foot Syndrome, Hand-foot Skin Reaction
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering.
- Trial name
- DermLight (NCT04979078)
- Testing
- Photobiomodulation therapy (PBMT)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jessa Hospital
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hand and Foot Syndrome, Erythrodysesthesia Syndrome
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of malignancy-related mortality. Capecitabine has been approved for the treatment of colorectal cancer as first-line therapy.
- Conditions
- Hand and Foot Syndrome, Erythrodysesthesia Syndrome, HFS, Colorectal Cancer
- Trial name
- HFS (NCT05327751)
- Testing
- Celecoxib 200mg, Capecitabine-based chemotherapy
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Hand-foot Syndrome
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome
A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in patients with early breast cancer.
- Trial name
- NCT05165069
- Testing
- Mecobalamin 5 MG Disintegrating Oral Tablet
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer
Prevention of Capecitabine Induced Hand and Foot Syndrome
Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores.
- Trial name
- NCT01291628
- Testing
- socks containing copper-oxide fibers
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Metastatic Renal Cell Carcinoma
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome…
- Trial name
- TROYA (NCT02789137)
- Where
- 23 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Pfizer
Hand and Foot Syndrome
TAR-0520 Gel in Hand and Foot Syndrome
Hand and Foot Syndrome (HFS) is a weii-established and frequent cutaneous adverse event of capecitabine used in the treatment of different cancers.HFS is charectirized by a variety of symptoms ranging from mild discomfort to a…
- Trial name
- TARIAN008 (NCT07457671)
- Testing
- TAR-0520 gel
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Tarian Pharma
Hepatocellular Carcinoma
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
Hepatocellular carcinoma (HCC) is a common fatal malignant tumor, although with the popularity of health examination, most patients were diagnosed as HCC in advanced stages so far.
- Trial name
- NCT02961998
- Testing
- Celecoxib, Sorafenib
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Palmar-Plantar Erythrodysesthesia Syndrome
Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine
The aim of this study is to evaluate the safety and efficacy of ATH008 cream in patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine therapy.
- Trial name
- NCT01316406
- Testing
- ATH008
- Where
- 26 sites in Belgium, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Advancell - Advanced In Vitro Cell Technologies, S.A.
Hand-Foot Syndrome
Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome
Hand foot skin reaction (HFS) from capecitabine is one of the most common adverse events from capecitabine. Urea cream has been proved its benefit to prevent HFS from sorafenib.
- Trial name
- NCT05348278
- Testing
- Urea cream
- Where
- Thailand
- Volunteers
- 214 people
- Sponsor
- Mahidol University
Hand-foot Syndrome
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated.
- Trial name
- NCT01609166
- Testing
- Allopurinol
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hand Foot Skin Syndrome
Topical Cosmetic Products for Hand and Foot Syndrome
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing…
- Trial name
- NCT06586073
- Testing
- cosmetic products
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Dermophisiologique s.r.l
Palmar and Plantar Erythema, Numbness of the Four Limbs
Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome
This study is a prospective, single-center, randomized, parallel-group, open-label clinical trial titled "Intervention with the 'Xu Xue Tong Luo Traditional Chinese Medicine Compound for Capecitabine-Related Hand-Foot Syndrome."…
- Conditions
- Palmar and Plantar Erythema, Numbness of the Four Limbs, Pain in the Distal Extremities, Peeling of the Soles and Palms
- Trial name
- NCT07883642
- Testing
- Twelve-Ingredient Prepared Sichuan Aconite Hand and Foot Bath, Standard Basic Nursing Interventions
- Volunteers
- 7 people
- Sponsor
- Emeishan Hospital of Traditional Chinese Medicine
HFS
Clinical Trial Evaluating the Efficacy and Safety of Uracil 0,5% Plasters in Oncology Patients Affected by Hand-foot Syndrome (HFS)
The goal of this clinical trial is to learn if The Uracil plaster works to treat mild HFS in adults under chemiotherapy. It will also learn about the safety .
- Trial name
- NCT07501442
- Testing
- Uracil 0,5% plasters, lenitive cream
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Wooshin Labottach Co., Ltd.
Ovarian Neoplasms, Breast Neoplasms
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or…
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Paresthesia
- Trial name
- NCT00746694
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Capecitabine, Hand-foot Syndrome
Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine.
- Conditions
- Capecitabine, Hand-foot Syndrome, Electroacupuncture, Self-administered Acupressure
- Trial name
- NCT06602167
- Testing
- True electroacupuncture + True self-administered acupressure, Doctor-prescribed treatment
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Qinghai University
Hand and Foot Skin Reaction, Hand and Foot Syndrome
Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine
The study was aimed to evaluate the efficacy of extra virgin olive oil (EVOO) supplementation compared to placebo to prevent HFS by observing changes in serum COX 2, malondialdehyde (MDA), and TNF α levels in breast cancer and…
- Conditions
- Hand and Foot Skin Reaction, Hand and Foot Syndrome, Capecitabine
- Trial name
- EVOO (NCT06188000)
- Testing
- Extra Virgin Olive Oil, Olive Oil
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Sriwijaya
Colorectal Cancer, Metastases
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator.
- Trial name
- SALTO (NCT01918852)
- Testing
- Capecitabine, Teysuno, Bevacizumab
- Where
- 24 sites in Netherlands
- Volunteers
- 161 people
- Sponsor
- Dutch Colorectal Cancer Group